Therapeutics that inhibit myostatin/activin A signaling are currently undergoing clinical trials for a wide range of indications which include sarcopenia, cancer cachexia, muscular dystrophy, sporadic inclusion body myositis and rehabilitation post-orthopedic surgery (for reviews, see34,54). The gene discussed is MSTN; the disease is inclusion body myositis.